文献速递儿童血液肿瘤与免疫儿童神经与发育行为

儿童门冬酰胺酶相关脑静脉窦血栓形成8例分析

[Analysis of 8 cases of asparaginase related cerebral venous sinus thrombosis in children].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2022-01-01

回顾性分析8例ALL或LBL患儿发生ASP相关CVST的临床资料,均为男童,发病年龄5~15岁,6例发生于初次诱导缓解期,7例以癫痫大发作为首发表现,影像均见上矢状窦血栓。及时抗凝治疗预后良好,机械取栓+溶栓联合抗凝可快速再通血管。

要点

  • ASP相关CVST多见于大龄男性患儿,好发于初次诱导缓解期。
  • 首发表现以癫痫大发作为主,上矢状窦为常见血栓部位。
  • 及时抗凝治疗安全有效,机械取栓+溶栓可快速再通血管。

核心结论

  • ASP相关CVST多发于大龄男性患儿,总体预后良好。
  • 及时抗凝治疗可改善预后,机械取栓+溶栓可快速再通血管。

研究设计与样本

  • 回顾性分析2016年11月至2021年10月郑州大学第一附属医院收治的8例ALL或LBL发生ASP相关CVST患儿的临床资料。

主要发现

  • 8例CVST患儿均为男童,其中ALL 6例、LBL 2例,发病年龄5~15岁。
  • 6例发生在初次诱导缓解阶段,首发表现为癫痫大发作7例。
  • 磁共振成像联合MRV显示均有上矢状窦血栓,合并脑出血5例,8例D二聚体均增高。
  • 随访3个月MRV显示除2例未抗凝治疗患儿血栓部分吸收外,其他患儿血栓基本全部吸收。
  • 1例死于ALL早期复发,7例存活患儿后续应用ASP无CVST反复或加重,除1例遗留左上肢肌力减低外余无神经系统后遗症。

关键数值与推荐

  • 3例接受机械取栓+溶栓联合抗凝治疗,3例单纯抗凝治疗,2例未抗凝治疗。
  • 机械取栓+溶栓术联合抗凝治疗患儿血栓吸收最快。

临床怎么用

  • 对ASP治疗期间出现癫痫发作的男童应警惕CVST,及时行磁共振成像联合MRV协助诊断。
  • 确诊后及时抗凝治疗安全有效,机械取栓+溶栓可快速再通血管。
  • CVST恢复后后续应用ASP未观察到CVST反复或加重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To summarize the clinical features, treatment and prognosis of asparaginase (ASP) related cerebral venous sinus thrombosis (CVST). Methods: Clinical profiles including age, sex, first symptoms, coagulation function, imaging findings, ASP type, treatment and prognosis of eight acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) children with ASP related CVST at the Department of Pediatrics, First Affiliated Hospital of Zhengzhou University from November 2016 to October 2021 were analyzed retrospectively. Results: Eight CVST children were all male, including 6 ALL and 2 LBL, with the onset age ranged from 5 to 15 years, 6 cases occurred in the stage of first induction remission, and the initial symptom were mainly epileptic seizures (7 cases). Magnetic resonance imaging combined magnetic resonance venography (MRV) showed the most common site of venous sinus enlargement was superior sagittal sinus (8 cases). Secondary cerebral hemorrhage was found in 5 cases. D-dimer elevated on the day of onset in all cases. Three patients were treated with intravascular mechanical thrombectomy and thrombolysis combined with anticoagulant therapy, 3 patients were treated with continuous anticoagulant therapy only, 2 patients were not treated with anticoagulant therapy. MRV follow-up for 3 months showed that the thrombi in patients were almost completely absorbed except in 2 patients who were not treated with anticoagulant therapy. Thrombolysis combined with anticoagulant therapy was the fastest way for thrombosis absorption. Among 8 patients, 1 died of early recurrence of ALL, and 7 patients accepted further asparaginase and no CVST recurrence or progression was found. There were no sequelae of nervous system except 1 patient with left upper limb muscle strength impairment. Conclusions: ASP related CVST is more common in older male children and the prognosis is good. ASP related CVST occurred mostly in the stage of first induction remission, and most initial manifestation is epileptic seizure. The superior sagittal region is a common site of thrombus, magnetic resonance imaging combined with MRV is helpful for accurately diagnosis. Timely anticoagulant treatment can improve the prognosis, and mechanical thrombectomy and thrombolysis can quickly recanalize the vessel. 目的: 总结门冬酰胺酶(ASP)相关脑静脉窦血栓形成(CVST)患儿的临床特点、治疗及预后。 方法: 回顾性分析2016年11月至2021年10月郑州大学第一附属医院收治的8例急性淋巴细胞白血病(ALL)或淋巴母细胞淋巴瘤(LBL)发生ASP相关CVST患儿的发病年龄、性别、首发症状、凝血功能、影像学特点、ASP的种类、治疗及转归等信息。 结果: 8例CVST患儿均为男童,其中ALL 6例、LBL 2例,发病年龄5~15岁。6例发生在初次诱导缓解阶段。首发表现为癫痫大发作7例。磁共振成像联合磁共振静脉成像(MRV)显示均有上矢状窦血栓,合并脑出血5例。8例患儿D二聚体均增高。治疗上,3例患儿接受机械取栓+溶栓联合抗凝治疗,3例单纯抗凝治疗,2例未抗凝治疗。随访3个月MRV显示除2例未抗凝治疗患儿血栓部分吸收外,其他患儿血栓基本全部吸收,机械取栓+溶栓术联合抗凝治疗患儿血栓吸收最快。1例患儿死于ALL早期复发,7例存活患儿后续应用ASP无CVST反复或加重,除1例遗留左上肢肌力减低,余均无神经系统后遗症。 结论: ASP治疗相关CVST多发于大龄男性患儿,总体预后良好,好发于初次诱导缓解期,多以癫痫大发作为首发表现,上矢状窦为常见血栓部位,磁共振成像联合MRV可协助准确诊断,及时抗凝治疗安全有效,机械取栓+溶栓可快速再通血管。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wei HX, Li B, Yang FD, et al. [Analysis of 8 cases of asparaginase related cerebral venous sinus thrombosis in children]. Zhonghua Er Ke Za Zhi. 2022. PMID: 35658364. doi:10.3760/cma.j.cn112140-20211112-00946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。